LifeMine Therapeutics
Develops fungal genome-derived therapeutics for organ transplant rejection
$263MSeries D+Series E
Role not disclosedLoading investors…
Activity from announced rounds
Develops fungal genome-derived therapeutics for organ transplant rejection
Develops next-generation RNAi therapeutics and engineering platform for multiple disease areas
Develops hormonal and non-hormonal male contraceptives for men and couples globally
Develops and manufactures adaptive robots for complex tasks
Develops next-generation therapies for immune-mediated inflammatory and fibrotic diseases
Develops medicines targeting historically undruggable protein targets in cancer